Crystal Crop Protection's ₹455.49 crore initial public offering (IPO) opened for public subscription today, November 18, 2026, with a price band of ₹259 to ₹272 per share. As of 10:05 A.M on the first day of bidding, the issue had been subscribed 0.03 times.
The IPO will remain open until November 20, 2026. The allotment is expected to be finalised on November 23, 2026, while the company’s shares are scheduled to list on the BSE and NSE on November 26, 2026.
The expected IPO schedule is as follows:
|
Event |
Date |
|
Subscription Opening Date |
18 November 2026 |
|
Subscription Closing Date |
20 November 2026 |
|
Basis of Allotment Date |
23 November 2026 |
|
Refund Initiation Date |
25 November 2026 |
|
Credit of Shares |
25 November 2026 |
|
Listing on BSE and NSE |
26 November 2026 |
Note: The allotment and listing dates are tentative and may be revised.
Explore other Upcoming IPOs on BSE and NSE.
[November 18, 2026, 10:05 A.M.]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.00x |
|
Non-Institutional Investors (NIIs) |
0.03x |
|
Retail Individual Investors (RIIs) |
0.05x |
|
Total |
0.03x |
The company intends to utilise the net proceeds from the fresh issue towards:
Established in 1994, Crystal Crop Protection Limited offers a diversified portfolio of crop solutions, with agrochemicals and seeds at its core. Its products include herbicides, fungicides, insecticides, biostimulants, bioprotectants, plant growth regulators, liquid fertilisers, micronutrients, and seeds for field crops, vegetables and flowers.
The company follows an integrated business model spanning R&D, seed breeding, technology-enabled manufacturing and pan-India distribution.
|
Particulars |
For the three-month period ended June 30, 2026 (in ₹ crore) |
FY26 (in ₹ crore) |
FY25 (in ₹ crore) |
|
Revenue from operations |
1,197.14 |
3,151.97 |
2,690.51 |
|
EBITDA |
241.78 |
456.23 |
315.28 |
|
Profit After Tax (PAT) |
135.78 |
144.91 |
118.39 |
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here